drugset / Trial / NCT03888859
ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma
Phase 0
Completed
12 enrolled
First Affiliated Hospital Xi'an Jiaotong University
Aeon Therapeutics (Shanghai) Co., Ltd. · collabEureka Therapeutics Inc. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
Clinical study to evaluate safety (primary objectives) and efficacy (secondary objective) of ET1402L1-ARTEMIS™2 T cells in patients with alpha fetoprotein positive (AFP+ ) hepatocellular carcinoma (HCC).
Timeline
- Start
- 2017-12-06
- Primary completion
- 2019-04-13
- Completion
- 2020-12-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ET1402L1-ARTEMIS™2 T cells | Cell therapy | — | Intravenous |